Protalix BioTherapeutics (PLX) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.69 +3.07%
Revenue Growth %: -33.6%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: -33.6%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.75 million versus the consensus estimate of $15.1 million.
Cash, cash equivalents and short-term bank deposits were approximately $28.6 million at June 30, 2022.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Eversource Energy (ES) Tops Q3 EPS by 18c; offers guidance
- Socket Mobile (SCKT) Reports Q3 Loss of $0.09
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
